RELMADA THERAPEUTICS, INC.
RLMDNasdaq
$5.24
↓ -4.0%Jul 17 close · end-of-day
Price
1Y↑ +764.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$453.8M
Enterprise Value
$219.8M
P/E
—
P/S
—
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$1.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-0.7%
ROIC
—
Debt / Equity
—
Net Cash
$234.0M
Return 1Y
+780.5%
Company profile
Relmada Therapeutics, Inc. focuses on developing various products for the treatment of central nervous system diseases and other disorders. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Its lead product candidate is Esmethadone, a new chemical entity and N-methyl-D-aspartate receptor antagonist.
- CEO
- Sergio Traversa
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Florida
- Website
- relmada.com
Management & directors
- Shenouda MagedChief Financial Officer
- Traversa SergioChief Executive Officer
- Ence ChuckCAO and COO
- Kelly Paul EdwardChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
RLMD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.22↓ -62.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$60.8M | -$125.7M | -$161.2M | -$103.7M | -$83.9M | -$59.1M |
| Net income | -$59.5M | -$125.8M | -$157.0M | $0.00 | $0.00 | $0.00 |
| Diluted EPS | — | -$7.16 | -$5.30 | -$3.28 | -$2.65 | -$1.45 |
| Operating cash flow | -$27.8M | -$91.9M | -$103.8M | -$51.7M | -$51.8M | -$45.8M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$18.8M | -$23.0M | -$19.1M | -$18.2M | -$10.2M | -$10.3M | -$20.3M | -$19.5M |
| Net income | -$17.8M | -$21.7M | $61.3M | -$17.6M | -$9.9M | -$10.1M | $37.5M | -$19.1M |
| Diluted EPS | -$0.59 | -$0.72 | -$0.62 | -$0.58 | -$0.30 | -$0.30 | -$0.27 | -$0.22 |
| Operating cash flow | -$13.3M | -$16.7M | -$8.8M | -$18.1M | -$6.4M | -$6.7M | -$14.6M | -$15.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 29, 2026
Jun 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-15 | TRAVERSA SERGIO· Chief Executive Officer | Buy | 27,500 | $4.12 | $113,300.00 | filing |
| 2025-12-15 | Shenouda Maged· Chief Financial Officer | Buy | 11,665 | $4.12 | $48,059.80 | filing |
| 2025-11-05 | Shenouda Maged· Chief Financial Officer | Buy | 500,000 | $2.20 | $1.1M | filing |
| 2025-11-05 | TRAVERSA SERGIO· Chief Executive Officer | Buy | 272,500 | $2.20 | $599,500.00 | filing |
| 2025-11-05 | Ence Chuck· CAO and COO | Buy | 136,000 | $2.20 | $299,200.00 | filing |
| 2025-11-05 | Kelly Paul Edward· Chief Operating Officer | Buy | 90,000 | $2.20 | $198,000.00 | filing |
| 2025-08-28 | TRAVERSA SERGIO· Chief Executive Officer | Buy | 55,976 | $0.74 | $41,422.24 | filing |
| 2025-08-27 | TRAVERSA SERGIO· Chief Executive Officer | Buy | 129,455 | $0.67 | $86,734.85 | filing |
| 2025-08-26 | TRAVERSA SERGIO· Chief Executive Officer | Buy | 80,545 | $0.62 | $49,937.90 | filing |
Latest 9 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.